US EditionRevumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia
Summary by cancernetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Revumenib safe, effective in AML related to NPM1 mutations
Oral therapy revumenib showed positive results in patients with relapsed or refractory acute myeloid leukemia (AML) driven by NPM1 mutations, with nearly half of participants achieving a clinical response in a pivotal Phase 2 trial. Syndax, revumenib’s developer, announced positive safety and efficacy results from the Phase 1/2 AUGMENT-101 trial (NCT04065399) in participants with this difficult to treat form of blood cancer. The study, “Menin in…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
